The Year Ahead
AS WE ENTER A NEW YEAR, WHAT ARE YOU MOST LOOKING FORWARD TO IN 2018?
SAHAR BEDROOD, MD, PhD
Every new year brings renewed hope that the vision set forth for the field of glaucoma and the needs of my patients exceeds my expectations. From a clinical and surgical standpoint, I look forward to implementing the newest products available to our glaucoma patients, including the use of rho-kinase inhibitors or injectable medication reservoirs to enhance IOP lowering in our nonsurgical patients. From a surgical standpoint, I look forward to seeing the next generation of MIGS devices (Figure 1A). Improving IOP while maintaining excellent visual outcomes in early disease is the future of glaucoma.
From a personal standpoint, I look forward to expanding on my early academic career. I aim to expand on my research endeavors while also playing a role as a mentor and educator for medical students, residents, and fellows (Figure 1B). Mentorship can be beneficial for the mentee because of the perspective, advice, and support given. However, I find it equally rewarding for me, the mentor, because it grounds me and always reminds me of why I am in this profession.
• Assistant Professor of Ophthalmology, Glaucoma Department, USC Roski Eye Institute, Los Angeles, California
• Financial disclosure: None acknowledged
STEVEN R. SARKISIAN JR, MD
I am looking forward to using the InnFocus MicroShunt (Santen; Figure 2)—another excellent weapon in our fight against glaucoma!
The InnFocus MicroShunt drainage system is an ab externo subconjunctival glaucoma device. It consists of a small microtube (about twice the size of an eyelash) that shunts aqueous fluid from the anterior chamber to a subconjunctival/sub-Tenon flap. The shunt is made of an inert biocompatible biomaterial called poly(styrene-block-isobutylene-block-styrene), or SIBS.
The InnFocus MicroShunt received the CE Mark in 2012. The final phase of a randomized clinical study comparing the InnFocus MicroShunt with trabeculectomy is underway in 29 centers in the United States and Europe. Hopefully 2018 marks the year we can begin implanting this device in clinical practice.
• Clinical Professor and Glaucoma Fellowship Director, Dean McGee Eye Institute, University of Oklahoma, Oklahoma City
• Financial disclosure: Consultant (Santen)